NCT05677438

A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia

A Phase 2, Randomized, Double-blind, Multi-center, Parallel-group Trial to Evaluate the Efficacy and Safety of CKD-498 in Female Patients With Androgenetic Alopecia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 121 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: Female
• Age: 19 Years – 54 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-centers, randomized, double-blind, parallel-group, Phase 2 Trial to evaluate the efficacy and safety of CKD-498 in female patients with Androgenetic Alopecia

Detailed description

Participants were randomly assigned in a 1:1:1:1 ratio to the following group: 3 dose of CKD-498 and Placebo. The patients are prescribed oral administration of the appropriate IP daily (3 tablets: actual medication and placebo) for 24 weeks.

Conditions

• Androgenetic Alopecia

Interventions

Type	Name	Description
DRUG	CKD-498 dose#1	oral, once daily, 24 weeks
DRUG	CKD-498 dose#2	oral, once daily, 24 weeks
DRUG	CKD-498 dose#3	oral, once daily, 24 weeks
DRUG	Placebo of CKD-498 dose#1	oral, once daily, 24 weeks
DRUG	Placebo of CKD-498 dose#2	oral, once daily, 24 weeks
DRUG	Placebo of CKD-498 dose#3	oral, once daily, 24 weeks

Timeline

• Start date: 2022-12-20
• Primary completion: 2023-12-15
• Completion: 2023-12-15
• First posted: 2023-01-10
• Last updated: 2024-06-28

Locations

1 site across 1 country: South Korea